Published in Proc Natl Acad Sci U S A on November 19, 2004
The role of mitochondria in apoptosis*. Annu Rev Genet (2009) 3.44
PUMA regulates intestinal progenitor cell radiosensitivity and gastrointestinal syndrome. Cell Stem Cell (2008) 2.68
The nuclear function of p53 is required for PUMA-mediated apoptosis induced by DNA damage. Proc Natl Acad Sci U S A (2007) 1.73
p53 independent induction of PUMA mediates intestinal apoptosis in response to ischaemia-reperfusion. Gut (2006) 1.56
Growth factors protect intestinal stem cells from radiation-induced apoptosis by suppressing PUMA through the PI3K/AKT/p53 axis. Oncogene (2009) 1.43
Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis. Proc Natl Acad Sci U S A (2010) 1.26
PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01. Mol Cancer Ther (2010) 1.13
Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth. Oncogene (2012) 1.04
Smac deficiency affects endoplasmic reticulum stress-induced apoptosis in human colon cancer cells. Mol Cell Pharmacol (2009) 0.93
Smac modulates chemosensitivity in head and neck cancer cells through the mitochondrial apoptotic pathway. Clin Cancer Res (2011) 0.87
Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma. Neoplasia (2007) 0.86
Targeting Bax interaction sites reveals that only homo-oligomerization sites are essential for its activation. Cell Death Differ (2013) 0.85
Sulindac Sulfide Differentially Induces Apoptosis in Smac-Proficient and -Deficient Human Colon Cancer Cells. Mol Cell Pharmacol (2009) 0.85
Role of apoptosis in colon cancer biology, therapy, and prevention. Curr Colorectal Cancer Rep (2013) 0.83
TAp73 promotes cell survival upon genotoxic stress by inhibiting p53 activity. Oncotarget (2014) 0.83
Promotion of Caspase Activation by Caspase-9-mediated Feedback Amplification of Mitochondrial Damage. J Clin Cell Immunol (2012) 0.83
BH3-based fusion artificial peptide induces apoptosis and targets human colon cancer. Mol Ther (2009) 0.82
BID mediates selective killing of APC-deficient cells in intestinal tumor suppression by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A (2014) 0.80
An apoptosis-independent role of SMAC in tumor suppression. Oncogene (2012) 0.77
SapC-DOPS nanovesicles induce Smac- and Bax-dependent apoptosis through mitochondrial activation in neuroblastomas. Mol Cancer (2015) 0.77
Cytotoxicity and cell cycle arrest induced by andrographolide lead to programmed cell death of MDA-MB-231 breast cancer cell line. J Biomed Sci (2016) 0.76
A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 35.21
Cancer genes and the pathways they control. Nat Med (2004) 24.22
Mitochondria and apoptosis. Science (1998) 23.41
Cell death: critical control points. Cell (2004) 22.56
Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell (1996) 16.73
Molecular characterization of mitochondrial apoptosis-inducing factor. Nature (1999) 14.41
Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell (2000) 11.90
The expanding role of mitochondria in apoptosis. Genes Dev (2001) 9.91
Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell (2000) 8.69
The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene (2003) 7.41
Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods (2002) 6.67
Endonuclease G is an apoptotic DNase when released from mitochondria. Nature (2001) 6.20
Role of BAX in the apoptotic response to anticancer agents. Science (2000) 5.07
A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science (2004) 4.95
Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer (2001) 4.62
PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci U S A (2003) 4.46
A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell (2003) 3.90
Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med (2002) 3.54
Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature (2000) 3.54
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med (2002) 3.03
Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A (1998) 2.83
TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev (2002) 2.31
Apoptosis-associated release of Smac/DIABLO from mitochondria requires active caspases and is blocked by Bcl-2. EMBO J (2001) 1.88
Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells. Cancer Biol Ther (2003) 1.80
X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res (2004) 1.77
Generation and characterization of Smac/DIABLO-deficient mice. Mol Cell Biol (2002) 1.61
Apoptosis in human cancer cells. Curr Opin Oncol (2004) 1.34
Destabilizing influences in apoptosis: sowing the seeds of IAP destruction. Cell (2002) 1.16
Chemoprevention strategies using NSAIDs and COX-2 inhibitors. Cancer Biol Ther (2003) 1.11
Sulindac metabolism: the importance of an intact colon. Clin Pharmacol Ther (1985) 0.97
The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan. Cancer Res (1997) 0.95
The kinetics of translocation of Smac/DIABLO from the mitochondria to the cytosol in HeLa cells. J Biol Chem (2002) 0.88
COX-2 inhibition, apoptosis, and chemoprevention by nonsteroidal anti-inflammatory drugs. Curr Med Chem (2000) 0.85
The saintly side of Smac/DIABLO: giving anticancer drug-induced apoptosis a boost. Cell Death Differ (2003) 0.84
The reduction of sulphinpyrazone and sulindac by intestinal bacteria. Xenobiotica (1987) 0.81
Sulphoxide reduction by rat intestinal flora and by Escherichia coli in vitro. Biochem Pharmacol (1995) 0.78
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
Cancer genome landscapes. Science (2013) 25.33
Cancer genes and the pathways they control. Nat Med (2004) 24.22
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
International network of cancer genome projects. Nature (2010) 20.35
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell (2007) 17.98
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A (2003) 12.91
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
The colorectal microRNAome. Proc Natl Acad Sci U S A (2006) 11.59
Allelic variation in human gene expression. Science (2002) 11.42
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature (2012) 10.17
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature (2009) 9.15
Using the transcriptome to annotate the genome. Nat Biotechnol (2002) 9.04
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA (2010) 8.21
Genomewide association study of leprosy. N Engl J Med (2009) 8.17
Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell (2005) 7.87
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol (2008) 7.86
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature (2003) 7.69
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat (2009) 7.68
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol (2005) 7.43
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. Proc Natl Acad Sci U S A (2008) 6.59
The antisense transcriptomes of human cells. Science (2008) 6.29
Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 6.29
Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med (2010) 6.08
The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science (2007) 6.01
Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A (2005) 5.91
Inactivation of hCDC4 can cause chromosomal instability. Nature (2004) 5.71
Aneuploidy and cancer. Nature (2004) 5.61
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res (2007) 5.54
Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet (2003) 5.51
Mutational analysis of the tyrosine kinome in colorectal cancers. Science (2003) 5.43
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science (2009) 5.31